Kornimate/medical-research-clean huggingface dataset:
effectiveness of mulligan mobilization technique and core stabilization exercise with knee osteoarthritis

Conditions: Exercise

Summary: osteoarthritis (oa) is a chronic disease process characterized by degeneration and inflammation in the joint cartilage and subchondral bone, synovial fluid and joint capsule. one of the most affected joints in oa is the knee joint, and the incidence of oa increases with age. different treatment approaches are used in the treatment of osteoarthritis. the aim of the study is to examine the effectiveness of mulligan technique and core exercises applied to female patients with knee osteoarthritis. in addition, the investigators did not find any study examining the effect of mulligan technique on static balance in the treatment of oa. this is the secondary aim of the study.


Eligibility criteria:
inclusion criteria: * being diagnosed with knee osteoarthritis * to be in the age range of 40-70 * no lower extremity surgery in the last 6 months. * agree to participate in the study exclusion criteria: * having had hip-knee replacement surgery * surgery planned in the last 6 months * having received physical therapy in the last 6 months * having uncontrollable hypertension and cardiac problems * having been diagnosed with rheumatoid arthritis

Keywords: pain, joint mulligan core stabilization
tele-assessment in individuals with covid-19

Conditions: Covid19

Summary: in most countries, after the measures taken to reduce the effects of the epidemic and quarantine practices, a remote screening tool has emerged in order to screen the needs developing after covid-19 and to make the necessary rehabilitation applications in time. sivan et al. a comprehensive multi-system phone scan of the covid-19 yorkshire rehabilitation screening tool (c19-yrs) has been developed by a multidisciplinary rehabilitation team. this study, which will be carried out using the c19-yrs tool and the 30-second sit-and-go test that evaluates functional capacity and mobility conditions, is expected to contribute to the clinical and literature since most of the studies on covid-19 focused only on the acute and subacute periods. in addition, considering the pandemic conditions all over the world, it will be possible to benefit from the advantages of the tele-assessment application and by reaching more people, possible clinical problems/needs and whether there is a change functional capacities in individuals after covid-19 will be identified.


Eligibility criteria:
inclusion criteria * being 18 years of age or older, * patients who have had covid-19 and whose treatment was completed and the pcr test was negative for 2 times or who passed the positive pcr test for 28 days, * individuals who can take and execute verbal orders, * giving consent on a voluntary basis exclusion criteria: * individuals who have not had covid 19 or acute-stage patients with covid-19 * individuals who refuse to participate in the tele-assessment * individuals with dementia, cognitive problems or communication problems

Keywords: covid-19 tele-assessment c19-yrs rehabilitation needs functional capacity
surgery compared to masking device for venous pulsatile tinnitus

Conditions: Tinnitus

Summary: the investigators aim to study whether surgical resurfacing of the sigmoid sinus and jugular bulb will result in elimination of venous pulsatile tinnitus.

currently there is no known treatments with efficacy for venous pulsatile tinnitus without any pathology. the investigators hope to learn that in surgery, resurfacing of the sigmoid sinus and jugular bulb (acoustic dampening) will eliminate symptoms such as pulsatile tinnitus in patients. the knowledge learned will significantly help treat and alleviate future patients that have pulsatile tinnitus. the purpose of the study is to examine whether surgical resurfacing of the sigmoid sinus and jugular bulb will result in elimination of pulsatile tinnitus in human subjects.

Eligibility criteria:
inclusion criteria: * unilateral venous pulsatile tinnitus * visual analogue score of severity \>5 exclusion criteria: * surgery exclusion criteria * only hearing ear * unfit for surgery / anesthesia * visual analogue score of severity 5 or less
prospective study of adjuvant radiotherapy in high risk bladder cancer.

Conditions: Bladder Cancer

Summary: this prospective interventional study aims at evaluating the safety and efficacy of an adjuvant radiation treatment in cases of muscle-invasive bladder cancer, submitted to radical cystectomy and presenting clinic-pathological characteristics of high risk of recurrence.

bladder cancer represents the ninth neoplasm in the world, with approximately 430,000 new cases diagnosed in 2012. of them, around 118,000 were diagnosed in europe, and 52,000 had died from this disease. patients with advanced bladder cancer (stage ≥pt3) have a five-year overall survival of \~50% after cystectomy and pelvic lymphadenectomy +/- chemotherapy with approximately half of recurrences in the pelvis, either as isolated failures or synchronous with distant metastases. in fact, radical cystectomy with or without chemotherapy has a 5-year overall survival of approximately 60% for patients with pathologic t2 disease confined to the bladder but only 10-40% for stage ≥pt3 when disease extends into the extravesicular tissues. pelvic failures after radical cystectomy are common, especially for ≥pt3 urothelial carcinoma with a cumulative incidence of locoregional failure of 32% at 5 years in the swog 8710 cohort. adjuvant radiation therapy (rt) can reduce locoregional failure and may even improve overall survival, but currently has no defined role, in part because of toxicity reported in older series using 1980s radiation techniques. an externally validated risk stratification to identify patients at highest risk for local-regional failure who are most likely to benefit from adjuvant rt has been developed based on pathologic t-stage, surgical margin status, and extent of the lymph node dissection. local-regional recurrence following radical cystectomy for patients with locally advanced urothelial carcinoma is common. the risk of local-regional recurrence is not diminished with chemotherapy, and salvage treatment is rarely successful. adjuvant rt can reduce locoregional failure and may even improve overall survival, but currently has no defined role, in part because of toxicity reported in older series using 1980s radiation techniques. several lines of evidence support the hypothesis that improved local control may lead to improved disease-free and overall survival. this prospective interventional study aims at evaluating the safety and efficacy of an adjuvant radiation treatment in cases of muscle-invasive bladder cancer, submitted to radical cystectomy and presenting clinic-pathological characteristics of high risk of recurrence.

Eligibility criteria:
inclusion criteria: * age \>18 years * karnofsky index \> 60 % (ecog \< 2) * histologically confirmed muscle-invasive bladder cancer (mibc) submitted to radical cystectomy. * pathological t-stage \> pt3, and/or pathological n-stage \> pn1, and/or residual tumor present after surgery (r\>1) * no distant metastases * written informed consent exclusion criteria: * prior rt in the pelvic region * presence of distant metastases * pregnancy * inability to consent
microbiota restoration therapy for recurrent clostridium difficile infection (punch cd3-ols)

Conditions: Clostridium Difficile Infection; Infection; Communicable Diseases

Summary: this is a prospective, multicenter, open-label phase 3 study of a microbiota suspension of intestinal microbes. patients who have had at least one recurrence of cdi after a primary episode and have completed at least one round of standard-of-care oral antibiotic therapy or have had at least two episodes of severe cdi resulting in hospitalization may be eligible for the study. subjects may receive a second rbx2660 enema if they are deemed treatment failures following the initial enema per the protocol-specified treatment failure definition.

this is a prospective, multicenter, open-label phase 3 study of a microbiota suspension of intestinal microbes. the primary assessments for this study are (i) safety via assessment of treatment-emergent adverse events and (ii) efficacy of rbx2660 preventing recurrent episodes of cdi measured at 8 weeks after treatment. follow-up office visits occur at 1 week and 8 weeks after completing the initial study treatment. telephone assessments occur at 4 weeks, and 4 and 6 months after the study. patients who have had at least one recurrence of cdi after a primary episode and have completed at least one round of standard-of-care oral antibiotic therapy or have had at least two episodes of severe cdi resulting in hospitalization may be eligible for the study. subjects may receive a second rbx2660 enema if they are deemed treatment failures following the initial enema per the protocol-specified treatment failure definition.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years old. 2. medical record documentation of either: a) a current diagnosis or history of recurrent cdi as determined by the treating physician, b) or has had at least two episodes of severe cdi resulting in hospitalization. 3. is currently taking or was just prescribed antibiotics to control cdi related diarrhea at the time of enrollment. \[note: subject's cdi diarrhea must be controlled (\<3 unformed/loose stools/day) while taking antibiotics during screening.\] exclusion criteria: 1. has continued cdi diarrhea despite being on a course of antibiotics prescribed for cdi treatment. 2. requires systemic antibiotic therapy for a condition other than cdi. 3. fecal microbiota transplant (fmt) within the past 6 months. 4. fmt with an associated serious adverse event related to the fmt product or procedure. 5. bezlotoxumab (cdi monoclonal antibodies) if received within the last year. 6. cd4 count \<200/mm\^3 during screening. 7. an absolute neutrophil count of \<1000 cells/µl during screening. 8. pregnant, breastfeeding, or intends to become pregnant during study participation.

Keywords: c. difficile diarrhea clostridium difficile cdi fmt fecal microbiota transplant microbiota restoration therapy diarrhea microbial suspension fecal transplant c difficile colitis clostridium difficile associated diarrhea c diff diarrhea c difficile c diff
postoperative outcomes of covid-19 patients who were hospitalized in a training and research hospital, who were operated on electively

Conditions: Long-term Consequences of COVID-19 Infection

Summary: the covid-19 infection has led to global health crisis. as the number of patients recovering from covid-19 infection increases, it is necessary to create an understanding of the health problems that concern them. reports of persistent and long-lasting effects are increasing after covid-19 infection .

data on postoperative outcomes in the patient population with covid-19 infection are limited. in more than half of these patients, pulmonary complications and mortality are seen between 19-24%. covid-19 infection positivity has been shown as an independent risk factor for surgical mortality. in this study, we aimed to examine the results of patients who were hospitalized and operated electively after they has covid-19. among the patients who were hospitalized and followed up in our hospital due to covid-19 infection between july 2020 and july 2021, those over the age 18 and opereted on electively will be included in the study. by accessing the hospital records, patients covid-19 treatment records, length of hospital stay, intensive care follow-up, processes, pulmonary support conditions, lung involvement, time until the operation, operation type, operation time, asa classification, anesthesia type, post-operative follow-up processes, post-operation intensive care needs, time to discharge and mortality will be examined. after the data of of the patients were recorded using spss19 program, statistical analysis will be performed using the arithmetic mean, median, standart deviation and chi-square test, which are among the measures of distribution and prevalence.

Eligibility criteria:
inclusion criteria: * over 18 years old * those who elective surgery * patients who have had covid-19 exclusion criteria: * emergency surgery * under 18 years old

Keywords: covid-19 postoperative care elective surgergy
registry of participants with generalized myasthenia gravis treated with alexion c5 inhibition therapies (c5its)

Conditions: Generalized Myasthenia Gravis

Summary: long-term, multicenter, multinational, observational, registry of patients with gmg that is designed to collect data on clinical outcomes and safety in patients prescribed alexion c5 inhibitor therapies (c5it) such as eculizumab (soliris®) and ravulizumab (ultomiris®).

at the time of enrollment in the registry, participant records will be queried for retrospective information about the participants' medical history and gmg disease treatment history. following enrollment, prospective data collection will be performed using data obtained as part of the routine clinical care and through patient-reported outcome methods in use. data will be collected using an electronic data capture system. the duration of data collection for the registry will be up to 5 years from the day of enrollment.

Eligibility criteria:
inclusion criteria: 1. participants with a diagnosis of gmg who are treated with alexion c5it at the time of enrollment, including patients previously treated with soliris or ultomiris and withdrawn from treatment. 2. capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions. 3. participants must have myasthenia gravis historical data, such as mg-adl and mgfa class, available to be enrolled in the registry. exclusion criteria: 1. participants currently enrolled in an alexion-sponsored interventional clinical study for treatment of gmg cannot be enrolled in the alexion gmg registry while enrolled/participating in the clinical study for gmg therapy.

Keywords: gmg soliris ultomiris alexion c5 inhibition therapy alexion c5it patient registry generalized myasthenia gravis alexion registry
safety and tolerability study of once-weekly oral aripiprazole in children and adolescents with tourette's disorder

Conditions: Tourette's Disorder

Summary: the goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with tourette's disorder.


Eligibility criteria:
inclusion criteria: * the participants successfully completed the final assessment visit in either study 31-10-272 (nct01418339) or 31-10-273 (nct01418352). the participants completed all required assessments for the week 8/early termination visit to be eligible for rollover in to this open-label trial. * written informed consent form (icf) obtained from a legally acceptable representative \& informed assent at baseline as applicable by trial center's institutional review board/independent ethics committee (irb/iec). * the participant, designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator. exclusion criteria: * the participants experienced adverse events (aes) during the double-blind study 31-10-272 (nct01418339) or 31-10-273 (nct01418352) that would, in the investigator's judgment, preclude further exposure to aripiprazole. * the participants had protocol violations during the double-blind trial considered major in the judgment of the investigator which would deem the participant a poor candidate for the trial. * a positive drug screen at baseline for cocaine, alcohol or other drugs of abuse which will result in early termination at week 1. * sexually active patients who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial and for 90 and 30 days following the last dose of study drug for male and female respectively. * participants representing risk of committing suicide. * body weight lower than 16 kg. * abnormal laboratory test results (platelet, hemoglobin, neutrophils, aspartate aminotransferase, alanine aminotransferase, creatinine) vital signs and electrocardiogram (ecg) results.

Keywords: tourette's disorder tic disorders
do patients who have had surgery for achalasia suffer from reflux

Conditions: Reflux

Summary: patients who have had laparoscopic surgery for the treatment of achalasia will be asked to have ph studies done in order to determine is these patients suffer from reflux after surgery.

the purpose of this study is to determine if patients who have laparoscopic heller myotomies for the treatment of achalasia suffer from reflux after the surgery. patients at our institution who have had surgery for achalasia will be asked to have ph studies done to determine whether or not these patients have reflux.

Eligibility criteria:
inclusion criteria: * patients who have had laparoscopic heller myotomies for the treatment of achalasia exclusion criteria: * patients under the age of 18 will not be included * patients who are receiving anti-reflux therapy will not be included

Keywords: laparoscopic heller myotomy, achalasia, reflux
a study to test if enzalutamide is effective and safe in prostate cancer patients who have never had hormone therapy

Conditions: Prostate Cancer

Summary: to evaluate the effect of enzalutamide on prostate specific antigen (psa) level in men with prostate cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed prostate cancer (all stages) for whom androgen deprivation therapy is indicated (except when indicated in a neoadjuvant/adjuvant therapy) * asymptomatic from prostate cancer * non-castrate level of testosterone (≥ 8 nmol/l (230 ng/dl)) at screening * psa ≥ 2 ng/ml at screening exclusion criteria: has previously or is currently receiving: * hormonal therapy with intent to treat prostate cancer * systemic glucocorticoids * chemotherapy with the intent to treat prostate cancer * opiate analgesics for pain from prostate cancer * radiation therapy for treatment of the primary tumor or metastases * has history of known or suspected brain or skull metastases or leptomeningeal disease * has history of seizure including febrile seizure or any condition that may predispose to seizure or history of loss of consciousness or transient ischemic attack * clinically significant cardiovascular disease

Keywords: bone turnover hormone-naïve prostate specific antigen prostate cancer
pre- and post-prandial levels of appetite regulatory hormones in adults

Conditions: Obesity; Appetitive Behavior

Summary: the present study aims to evaluate in adults with normal weight and with overweight or obesity who live in the city of la plata the circulating levels of various hormones that regulate appetite and the gene expression of their receptors in peripheral blood mononuclear cells before and after food intake.

the investigators plan a single test meal study in males and females with normal weight (nw) or overweight/obesity (ow/ob) assessing whether plasma appetite regulatory hormones levels are associated with different metabolic and anthropometric variables as well as with appetite sensations.

Eligibility criteria:
inclusion criteria: * adult individuals body mass index\> 18.5 kg∙m-2 exclusion criteria: * chronic medical illness, personal history of diabetes, history of medical condition, or medication related to obesity or diabetes risk status. pregnancy
stop persistent af

Conditions: Atrial Fibrillation

Summary: to demonstrate safety and effectiveness of the arctic front advance™ and freezor max® cardiac cryoablation catheters for the treatment of drug refractory recurrent symptomatic persistent atrial fibrillation (af).


Eligibility criteria:
inclusion criteria: * documentation of symptomatic persistent af: defined as having a continuous episode lasting longer than 7 days but less than 6 months documented by consecutive ecg recordings or defined as having a continuous episode lasting longer than 7 days but less than 6 months documented by an ecg recording and one doctor note indicating patient had symptoms consistent with af * failure or intolerance of at least one class i or iii antiarrhythmic drug * age 18 or older (or older than 18 if required by local law) exclusion criteria: * left atrial diameter \> 5.0 cm (anteroposterior) * prior left atrial ablation or surgical procedure (including left atrial appendage closures) * presence or likely implant of a permanent pacemaker, biventricular pacemaker, loop recorder, or any type of implantable cardiac defibrillator (with or without biventricular pacing function) within 12 months * presence of any pulmonary vein stents * presence of any pre-existing pulmonary vein stenosis * pre-existing hemidiaphragmatic paralysis * presence of any cardiac valve prosthesis * +3 and +4 mitral valve regurgitation or stenosis * any cardiac surgery, myocardial infarction, percutaneous coronary intervention (pci) / percutaneous transluminal coronary angioplasty (ptca) or coronary artery stenting which occurred during the 3 month interval preceding the consent date * unstable angina * new york heart association (nyha) class iii or iv congestive heart failure and/or documented left ventricular ejection fraction (lvef) less than or equal to 35% measure by acceptable cardiac testing (e.g. transthoracic echocardiogram (tte)) * primary pulmonary hypertension * rheumatic heart disease * thrombocytosis, thrombocytopenia * any condition contraindicating chronic anticoagulation * active systemic infection * hypertrophic cardiomyopathy * cryoglobulinemia * uncontrolled hyperthyroidism * any cerebral ischemic event (strokes or transient ischemic attacks (tias)) which occurred during the 6 month interval preceding the consent date * any woman known to be pregnant or breastfeeding, or any woman of child bearing potential who is not on a reliable form of birth regulation method or abstinence * life expectancy less than one year * current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of the study not pre-approved by medtronic * known allergies or hypersensitivities to adhesives * known drug or alcohol dependency * unwilling or unable to comply fully with study procedures and follow-up
exercise and cardiac stunning during hd

Conditions: End-stage Kidney Disease; Hemodialysis

Summary: the purpose of this study is to determine the effect of a 12-week cycling during hemodialysis program on hemodialysis-induced myocardial stunning in adult individuals receiving hemodialysis.

people with kidney failure receiving chronic hemodialysis (hd) suffer from post-hd treatment fatigue, poor functional status and high rates of cardiac failure and death. previous work has shown that these outcomes are correlated with recurrent ischemic cardiac injury (myocardial stunning) that occurs during hd treatments. myocardial stunning, identified by regional cardiac wall motion abnormalities (rwma), is common during hd. intradialytic cycling (during hd) decreases hd-induced stunning, and may improve adverse outcomes associated with stunning. we will use echocardiography (echo) to understand the effects of intradialytic aerobic exercise on myocardial stunning and hd-related symptoms.

Eligibility criteria:
inclusion criteria: * adults greater than or equal to 18 years old (no upper age limit); who are greater than; 3 months after starting maintenance hemodialysis * no expected change in dialysis modality, elective surgery or relocation outside of study site during the intervention period (16 weeks) * assessed to be safe and able to exercise by the hemodialysis unit nephrologist * able to communicate in english and provide written informed consent * must be dialyzing thrice weekly exclusion criteria: * acute coronary syndrome in the past 3 months * unstable arrhythmia * shortness of breath at rest or with minimal activity (nyha class 4) * symptomatic hypoglycemia (\&gt;2x/week in week prior to enrolment) * participating in clinical intradialytic cycling program in last 3 months (if a clinical program exists)

Keywords: intradialytic exercise